带量非带量和进口复方甘草酸苷治疗化疗肝损伤的药物经济学评价  

Pharmacoeconomics Evaluation of Compound Glycyrrhizin:Collected,Non-collected and Imported in the Treatment of Chemotherapy Induced Liver Injury

作　　者：苗秋丽[1] 丁一迪 闫荟羽[3] MIAO Qiu-Li;DING Yi-Di;YAN Hui-Yu(Department of Pharmacy,The First Hospital of Jilin University,Changchun 130021,China;Department of Medical Technology,Heze Vocational College of Home Economics,Heze 274000,China;Department of Clinical Research,The First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院乐群院区药学部,长春130021 [2]菏泽家政职业学院医药技术系,山东菏泽274000 [3]吉林大学第一医院临床研究部,长春130021

出　　处：《中国药物经济学》2024年第11期11-15,共5页China Journal of Pharmaceutical Economics

基　　金：吉林省教育厅科学技术研究项目资助(JJKH20211226KJ);吉林省教育厅科学技术研究项目资助(JJKH20201120KJ);吴阶平医学基金会临床科研项目(320.6750.2020-11-18)。

摘　　要：目的评价带量非带量和进口复方甘草酸苷治疗化疗肝损伤的经济性。方法选取2021年5月至2023年5月就诊于吉林大学第一医院的127例化疗相关药物性肝损伤(DILI)患者作为研究对象,按照用药品种不同为3组:A组(集中带量采购的复方甘草酸苷)39例、B组(非集中带量采购的复方甘草酸苷)47例、C组(进口复方甘草酸苷)41例。以治疗有效率为效果指标,建立决策树模型对3种复方甘草酸苷治疗化疗相关DILI进行成本-效果分析,并进行敏感性分析。结果成本-效果分析显示,3组的成本-效果比(C/E)分别为A组0.40、B组3.80、C组4.27,A组最小,C组最大。3组治疗有效率比较差异无统计学意义,无需计算增量成本-效果比,因此A组治疗方案更具经济性。敏感性分析结果与成本-效果分析结果基本一致,表明成本-效果分析结果可靠。结论在带量采购、非带量采购和进口复方甘草酸苷治疗化疗相关DILI方案中,带量采购复方甘草酸苷更具成本-效果优势。Objective To evaluate the economic effects of collected,non-collected and imported glycyrrhizin in the treatment of chemotherapy liver injury.Methods A retrospective analysis was conducted on the medical records of hospitalized patients with non-small cell lung cancer diagnosed at the First Hospital of Jilin University from May 2021 to May 2023,who developed liver injury after chemotherapy.The patients were divided into three groups based on the use of chemotherapy related DILI drugs,Group A consisting of 39 patients used centralized purchasing of compound glycyrrhetinic acid glycosides,while Group B of 47 patients relied on non-centralized purchasing of compound glycyrrhetinic acid glycosides,and another 41 patients in Group C used imported compound glycyrrhetinic acid glycosides.Taking the clinical treatment efficiency as the effect index,a decision tree model was established to analyze the cost-effectiveness and sensitivity of three compound glycyrrhizin in the treatment of chemotherapyrelated DILI.Results Cost-effectiveness analysis showed that the cost-effectiveness ratio(C/E)of the three groups were 0.40 in group A,3.80 in group B and 4.27 in group C,respectively,with the smallest in group A and the largest in group C.There was no statistical significance in the comparison of treatment effectiveness among the three groups,and the incremental cost-effectiveness ratio was not needed to be calculated,so the treatment plan of group A was more economical.The results of sensitivity analysis are basically consistent with those of cost-effectiveness analysis,which indicates that the results of cost-effectiveness analysis are reliable.Conclusion Centralized,non-centralized and imported compound glycyrrhetinic acid glycosides in the treatment of chemotherapy related DILI,collected compound glycyrrhetinic acid glycosides has more cost-effective advantages.

关 键 词：带量采购 复方甘草酸苷 药物性肝损伤 药物经济学 

分 类 号：R575.5[医药卫生—消化系统] R956[医药卫生—内科学]